Phase II trial of fludarabine monophosphate in patients with mantle- cell lymphomas

Journal of Clinical Oncology

Volumn 16, Issue 2, 1998, Pages 579-583

  Decaudin, Didier ^a   Bosq, Jacques ^a   Tertian, Gérard ^a   Nedellec, Gérard ^a   Bennaceur, Annelise ^a   Venuat, Anne Marie ^a   Bayle, Chantal ^a   Carde, Patrice ^a   Bendahmane, Belgendouz ^a   Hayat, Marcel ^a   Munck, Jean Nicolas ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE PHOSPHATE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL PNEUMONIA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; FEMALE; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MANTLE CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0031896096     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.2.579     Document Type: Article

References (34)

1. Banks PM, Chan J, Cleary ML, et al: Mantle cell lymphoma: A proposal for unification of morphologic, immunologic and molecular data. Am J Surg Pathol 16:637-640, 1992
2. Lennert K, Stein H, Kaiserling E: Cytological and functional criteria for the classification of malignant lymphomata. Br J Cancer 31:29-43, 1964 (suppl 2)
3. Berard CW, Dorfman RF: Histopathology of malignant lymphomas. Clin Haematol 3:39-76, 1974
4. Weisenburger DD, Kim H, Rappaport H: Mantle-zone lymphoma: A follicular variant of intermediate lymphocytic lymphoma. Cancer 49:1429-1438, 1982
5. The non-Hodgkin's lymphoma pathologic classification project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a Working Formulation for Clinical Usage. Cancer 49:2112-2135, 1982
6. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
7. Zucca E, Stein H, Coiffier B: European Lymphoma Task Force (ELTF): Report of the workshop on mantle cell lymphoma (MCL). Ann Oncol 5:507-511, 1994
8. Decaudin D, Bosq J, Munck JN, et al: Mantle cell lymphomas: Characteristics, natural history and prognostic factors of 45 cases. Leuk Lymphoma 26:539-550, 1997
9. Berger F, Felman P, Sonet A, et al: Nonfollicular small B-cell lymphomas: A heterogeneous group of patients with distinct clinical features and outcome. Blood 83:2829-2835, 1994
10. Duggan M, Weisenburger DD, Ye Y, et al: Mantle zone lymphoma: A clinicopathologic study of 22 cases. Cancer 66:522-529, 1990
11. Fisher R, Dahlberg S, Nathwani B, et al: A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): A Southwest Oncology Group study. Blood 85:1075-1082, 1995
12. Norton AJ, Matthews J, Pappa V, et al: Mantle cell lymphoma: Natural history defined in a serially biopsied population over a 20-year period. Ann Oncol 6:249-256, 1995
13. Pittaluga S, Wlodarska I, Stul MS, et al: Mantle cell lymphoma: A clinicopathological study of 55 cases. Histopathology 26:17-24, 1995
14. Shivdasani RA, Hess JL, Skarin AT, et al: Intermediate lymphocytic lymphoma: Clinical and pathological features of a recently characterized subtype of non-Hodgkin's lymphoma. J Clin Oncol 11:802-811, 1993
15. Teodorovic I, Pittaluga S, Kluin-Nelemans JC, et al: Efficacy of four different regimens in 64 mantle-cell lymphoma cases: Clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. J Clin Oncol 13:2819-2826, 1995
16. Velders GA, Kluin-Nelemans JC, De Boer CJ, et al: Mantle-cell lymphoma: A population-based clinical study. J Clin Oncol 14:1269-1274, 1996
17. Weisenburger DD, Armitage JO: Mantle cell lymphoma - an entity comes of age. Blood 87:4483-4494, 1996
18. Zucca E, Roggero E, Pinotti G, et al: Patterns of survival in mantle cell lymphoma. Ann Oncol 6:257-262, 1995
19. Plunkett W, Gandhi V, Huang P, et al: Fludarabine: Pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol 20:2-12, 1993 (suppl 7)
20. Keating MJ, Estey E, O'Brien S, et al: Clinical experience with fludarabine in leukaemia. Drugs 47:39-49, 1994 (suppl 6)
21. Solal-Celigny P, Brice P, Brousse N, et al: Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 14:514-519, 1996
22. Leiby JM, Snider KM, Kraut EH, et al: Phase II trial of 9-β-D-Arabinofuranosyl-2-fluoroadenine 5′-monophosphate in non-Hodgkin's lymphoma: Prospective comparison of response with deoxycytidine kinase activity. Cancer Res 47:2719-2722, 1987
23. Redman JR, Cabanillas F, Velasquez WS, et al: Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma. J Clin Oncol 10:790-794, 1992
24. Hochster HS, Kim K, Green MD, et al: Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: Results of an Eastern Cooperative Oncology Group study. J Clin Oncol 10:28-32, 1992
25. Warnke R, Levy R: Detection of T and B cell antigens with hybridoma monoclonal antibodies. A biotin-avidin-horseradish peroxidase method. J Histochem Cytochem 28:771-776, 1980
26. Dutrillaux B, Lejeune J: On a new technique of human karyotype study. C R Acad Sci Paris 272:2638-2640, 1971
27. Mitelman F: ISCN: Guidelines for Cancer Cytogenetics: Supplement to An International System for Cytogenetic Nomenclature. Bâle, Switzerland, Ed Basel:Karger, 1991
28. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
29. Keating MJ, McLaughlin P, Plunkett W, et al: Fludarabine -present status and future developments in chronic lymphocytic leukemia and lymphoma. Ann Oncol 5:S79-S83, 1994 (suppl 2)
30. Pigaditou A, Rohatiner AZS, Whelan JS, et al: Fludarabine in low-grade lymphoma. Semin Oncol 20:24-27, 1993 (suppl 7)
31. Robertson LE, Chubb S, Meyn RE, et al: Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine. Blood 81:143-150, 1993
32. O'Brien S, Kantarjian H, Beran M, et al: Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis derived prognostic model for response to treatment. Blood 82:1695-1700, 1993
33. Hiddeman W, Unterhalt M, Pott C, et al: Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: A phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group. Semin Oncol 20:28-31, 1993 (suppl 7)
34. Zinzani PL, Lauria F, Rondelly D, et al: Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Ann Oncol 4:575-578, 1993